An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis.
about
The influence of Myrj 59 on the solubility, toxicity and activity of amphotericin BLimited protection by small unilamellar liposomes against the renal tubular toxicity induced by repeated amphotericin B infusions in ratsIn vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with IntralipidPractice guidelines for lipid-based amphotericin B in stem cell transplant recipients.SolEmuls technology: a way to overcome the drawback of parenteral administration of insoluble drugs.Amphotericin B in lipid emulsion: stability, compatibility, and in vitro antifungal activity.Treatment of murine candidiasis and cryptococcosis with amphotericin B incorporated into egg lecithin-bile salt mixed micelles.Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study.Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patientsAmphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplantsPharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia.Serum pharmacology of amphotericin B applied in lipid emulsions.Amphotericin B: delivery systems.Carrier effects on biological activity of amphotericin B.Comparison of nephrotoxicities of different polyoxyethyleneglycol formulations of amphotericin B in rats.Amphotericin B lipid complex therapy of experimental fungal infections in miceRole of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity.Concentrations in serum and distribution in tissue of free and liposomal amphotericin B in rats during continuous intralipid infusion.Amphotericin B toxicity reduced by administration in fat emulsion.The interaction of liposomal amphotericin B and serum lipoproteins within the biological milieu.Intralipid in prophylaxis of amphotericin B nephrotoxicity.Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia.Modification of amphotericin B's therapeutic index by increasing its association with serum high-density lipoproteins.Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis.Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B.Amphotericin B and its delivery by liposomal and lipid formulations.Solubilizing poorly soluble antimycotic agents by emulsification via a solvent-free process.In search of the amazing technicolour dream coat for amphotericin B.Gastrointestinal absorption of phenytoin from an oil-in-water microemulsion.PHARMACOKINETIC STUDIES OF IN-SITU LIPOSOMAL PREPARATION CONTAINING AMPHOTERICIN B COMPLEXED WITH DIFFERENT CHEMICALLY MODIFIED beta-CYCLODEXTRINS.Pharmacologic influence on nutrition support therapy: use of propofol in a patient receiving combined enteral and parenteral nutrition support.Amphotericin B is incompatible with lipid emulsions.
P2860
Q28322976-848EF99A-0D4A-4AEB-A307-4682639B481CQ28333669-D7192009-4163-4FBF-9EAD-8928276C90ADQ28369708-82C7C64D-42FB-46C6-93C3-9970CC33BBE4Q32052950-AC951267-6E22-4B0A-9518-DE0D355A04B1Q33304020-05F6B0A7-2721-45C1-8591-75EC7023F9D1Q33692176-EED883C7-3C02-4449-8C46-C4C62711AE3FQ33749073-FEACD2FE-1309-4673-93BA-6FC14E352935Q33824631-6D5B6B99-0427-4DAC-802D-7F9959D23B8EQ33976955-53C30F2A-C188-41A3-95C6-ABFDE2DB468DQ34294886-35DED180-3BDF-46CF-B765-85A7C8CC4DA7Q35118404-8B6D4D3E-FD09-4DEF-BE3B-44277D501791Q35122944-EF0BD36D-9CC7-41C2-B940-A70870AAA862Q35134565-9C7B0634-8C63-4212-8793-DD5474C04972Q35249721-A2C969E1-839F-45F1-9561-DC7D176F688EQ35372581-691EE4FA-05B5-46B0-82DD-FB7678889F1EQ35885347-9506A8B4-969C-4647-8A77-13EC7B0C7BDBQ36753279-EBDF590D-5FB9-4C7F-A517-8FF350BC683FQ38077678-D8D57EE5-EEAF-4F28-B5C1-47AFD9F39E54Q40286515-770D8A8A-A6C9-4B0E-8A64-CD55A32222AEQ40471190-92D7FB4A-AB35-41E0-A812-4C3BC79A8B74Q40499103-1085A979-A20D-47E9-B87D-CD0D530CC703Q40582560-84D4743A-F772-49F4-85C3-FB051D756D8DQ40677144-D4D2CE8E-F5F3-45F9-BE09-75CFB16DF61AQ40699353-C6B1D5D0-9F03-4B84-AC4E-2665972A6C3FQ40727940-DF6205E4-7F25-4D98-8864-78A0788D3C7EQ40730943-EF5C678F-A106-449D-8F3F-0E7DBED641D5Q40831603-1E82E127-EB44-4E7E-A427-DAA22A9F11E0Q41990421-E8E63D48-BB88-47E4-A75C-896A11F1F749Q42544559-C2AD7254-C38B-4D0A-A4E9-65E5060ECC99Q42602222-85D577C7-7307-4B27-B6F6-9EAF019FFE5CQ45967355-DF0AC047-9C1E-47F8-84FE-82CC1617EDC1Q51564667-47D71AD5-878D-4E4B-8FDE-7AAC5B010D95Q54122029-12EE8246-A75C-4E78-A88F-AE3AC8EBA58F
P2860
An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh-hant
name
An emulsion formulation of amp ...... g systemic murine candidiasis.
@en
An emulsion formulation of amp ...... g systemic murine candidiasis.
@nl
type
label
An emulsion formulation of amp ...... g systemic murine candidiasis.
@en
An emulsion formulation of amp ...... g systemic murine candidiasis.
@nl
prefLabel
An emulsion formulation of amp ...... g systemic murine candidiasis.
@en
An emulsion formulation of amp ...... g systemic murine candidiasis.
@nl
P2093
P356
P1476
An emulsion formulation of amp ...... g systemic murine candidiasis.
@en
P2093
Bugelski P
Goldstein R
P304
P356
10.1093/INFDIS/158.5.1065
P407
P577
1988-11-01T00:00:00Z